Back to GetFilings.com
FORM 10-Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2005
----------------------------
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________to ________
Commission file number 0-19777
DUSA Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
New Jersey 22-3103129
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
25 Upton Drive
Wilmington, Massachusetts 01887
(Address of principal executive offices)
(Zip Code)
(978) 657-7500
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 month (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No
----- ----
Indicate by check mark whether the Registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act).
Yes X No
----- ----
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date.
16,920,697 shares as of May 5, 2005
PART 1.
ITEM 1. FINANCIAL STATEMENTS
DUSA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
MARCH 31, DECEMBER 31,
2005 2004
(UNAUDITED)
----------------- ----------------
ASSETS
CURRENT ASSETS
Cash and cash equivalents $712,837 $2,928,143
Marketable securities 42,963,680 46,222,969
Accrued interest receivable 627,891 641,797
Accounts receivable, net 815,942 711,016
Inventory, net 1,990,251 1,417,160
Prepaids and other current assets 834,363 830,895
----------------- ----------------
TOTAL CURRENT ASSETS 47,944,964 52,751,980
Restricted cash 140,989 140,764
Property, plant and equipment, net 3,413,108 3,481,888
Deferred charges and other assets 264,322 276,256
----------------- ----------------
TOTAL ASSETS $51,763,383 $56,650,888
================= ================
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable $470,286 $857,268
Accrued compensation 620,823 963,607
Other accrued expenses 2,022,417 1,901,841
Deferred revenue 315,638 230,715
----------------- ----------------
TOTAL CURRENT LIABILITIES 3,429,164 3,953,431
Other liabilities 194,528 190,439
----------------- ----------------
TOTAL LIABILITIES 3,623,692 4,143,870
----------------- ----------------
COMMITMENTS AND CONTINGENCIES (NOTE 9)
SHAREHOLDERS' EQUITY
Capital Stock
Authorized: 100,000,000 shares; 40,000,000 shares designated as common
stock, no par, and 60,000,000 shares issuable in series or classes; and
40,000 junior Series A preferred shares. Issued and outstanding:
16,919,447 and 16,876,822 shares of common stock, no par, at March 31,
2005 and December 31, 2004, respectively. 124,870,719 124,698,059
Additional paid-in capital 2,035,783 2,016,339
Accumulated deficit (78,870,376) (74,538,761)
Accumulated other comprehensive income 103,565 331,381
----------------- ----------------
TOTAL SHAREHOLDERS' EQUITY 48,139,691 52,507,018
----------------- ----------------
$51,763,383 $56,650,888
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY ================= ================
See the accompanying Notes to the Condensed Consolidated Financial Statements.
2
DUSA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31,
2005 2004
(UNAUDITED) (UNAUDITED)
----------------- ---------------
Kerastick(R) Product Sales, net $2,510,089 $895,400
BLU-U(R) Product Sales, net 858,525 360,285
----------------- ---------------
PRODUCT SALES, NET 3,368,614 1,255,685
Kerastick(R) Cost of Product Sales and Royalties 979,242 430,630
BLU-U(R) Cost of Product Sales 1,024,386 395,375
----------------- ---------------
COST OF PRODUCT SALES AND ROYALTIES 2,003,628 826,005
----------------- ---------------
TOTAL GROSS MARGIN 1,364,986 429,680
----------------- ---------------
OPERATING COSTS
Research and development 1,595,717 1,687,766
Marketing and sales 2,785,402 1,367,458
General and administrative 1,682,479 2,175,247
----------------- ---------------
TOTAL OPERATING COSTS 6,063,598 5,230,471
----------------- ---------------
LOSS FROM OPERATIONS (4,698,612) (4,800,791)
----------------- ---------------
OTHER INCOME
Interest income, net 366,997 399,137
----------------- ---------------
NET LOSS $(4,331,615) $(4,401,654)
================= ===============
BASIC AND DILUTED NET LOSS PER COMMON SHARE $(0.26) $(0.30)
================= ===============
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED 16,908,351 14,802,474
================= ===============
See the accompanying Notes to the Condensed Consolidated Financial Statements.
3
DUSA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
THREE MONTHS ENDED MARCH 31,
2005 2004
(UNAUDITED) (UNAUDITED)
----------------- ------------------
CASH FLOWS PROVIDED BY (USED IN) OPERATING ACTIVITIES
Net loss $(4,331,615) $(4,401,654)
Adjustments to reconcile net loss to net cash used in operating
activities:
Amortization of premiums and accretion of discounts marketable 157,611 27,518
securities available for sale, net
Depreciation and amortization 271,089 460,711
Issuance of options to consultants - 240,753
Stock-based compensation 19,444 -
Changes in other assets and liabilities impacting cash flows from
operations:
Accrued interest receivable 13,906 161,428
Accounts receivable (104,926) 35,771
Inventory (573,091) (128,650)
Prepaids and other current assets (3,468) 81,954
Restricted cash (225) (317)
Deferred charges and other assets 11,934 -
Accounts payable (386,982) (484,448)
Accrued compensation and other accrued expenses (222,208) 443,503
Deferred revenue 84,923 91,812
Other liabilities 4,089 -
----------------- ------------------
NET CASH USED IN OPERATING ACTIVITIES (5,059,519) (3,471,619)
----------------- ------------------
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES
Purchases of marketable securities (11,578,287) -
Proceeds from maturing and sales of marketable securities 14,452,149 4,000,000
Purchases of property, plant and equipment (202,309) (222,516)
----------------- ------------------
NET CASH PROVIDED BY INVESTING ACTIVITIES 2,671,553 3,777,484
----------------- ------------------
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES
Issuance of common stock (net of stock offering costs of $214,402) - 24,535,598
Proceeds from exercise of options 172,660 297,291
Payments of long-term debt - (67,500)
----------------- ------------------
NET CASH PROVIDED BY FINANCING ACTIVITIES 172,660 24,765,389
----------------- ------------------
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (2,215,306) 25,071,254
----------------- ------------------
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 2,928,143 4,294,482
----------------- ------------------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 712,837 $29,365,736
================= ==================
On March 2, 2004, the Company issued 135,000 shares of its common stock in
a private placement at $11.00 per share as commission and non-refundable
retainer to the placement agent for a total value of $1,485,000.
See the accompanying Notes to the Condensed Consolidated Financial Statements.
4
DUSA PHARMACEUTICALS, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1) BASIS OF PRESENTATION
The Condensed Consolidated Balance Sheet as of March 31, 2005, and the
Condensed Consolidated Statements of Operations and Cash Flows for the three
months ended March 31, 2005 and 2004 of DUSA Pharmaceuticals, Inc. (the
"Company" or "DUSA") have been prepared in accordance with accounting principles
generally accepted in the United States of America. These condensed consolidated
financial statements are unaudited but include all normal recurring adjustments,
which management of the Company believes to be necessary for fair presentation
of the periods presented. The results of the Company's operations for any
interim period are not necessarily indicative of the results of the Company's
operations for any other interim period or for a full year.
Certain information and footnote disclosures normally included in financial
statements prepared in accordance with accounting principles generally accepted
in the United States of America have been condensed or omitted. These condensed
consolidated financial statements should be read in conjunction with the
Company's December 31, 2004 audited consolidated financial statements and notes
thereto. Certain amounts for 2004 have been reclassified to conform to the
current year presentation. Such reclassifications had no impact on the net loss
or shareholders' equity for any period presented.
2) MARKETABLE SECURITIES
The Company's marketable securities consist of securities of the United
States government and its agencies and corporate bonds, all classified as
available-for-sale. As of March 31, 2005, current yields range from 2.54% to
7.84% and maturity dates range from April 1, 2005 to June 15, 2008. The
estimated fair value and cost of marketable securities at March 31, 2005 and
December 31, 2004 are as follows:
MARCH 31, 2005
-----------------------------------------------------------------
AMORTIZED GROSS GROSS FAIR VALUE
COST UNREALIZED UNREALIZED
GAINS LOSSES
------------- ------------- -------------- --------------
United States government securities $23,199,574 $197,745 ($34,681) $23,362,638
Corporate securities 19,660,541 1,185 (60,684) 19,601,042
------------- ------------- -------------- --------------
Total marketable securities available
for sale $42,860,115 $198,930 ($95,365) $42,963,680
============= ============= ============== ==============
5
DUSA PHARMACEUTICALS, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
DECEMBER 31, 2004
-----------------------------------------------------------------
AMORTIZED GROSS GROSS FAIR VALUE
COST UNREALIZED UNREALIZED
GAINS LOSSES
------------- ------------- -------------- --------------
United States government securities $27,266,271 $389,585 ($15,315) $27,640,541
Corporate securities 18,625,317 504 (43,393) 18,582,428
------------- ------------- -------------- --------------
Total marketable securities available
for sale $45,891,588 $390,089 ($58,708) $46,222,969
============= ============= ============== ==============
The change in net unrealized gains and losses on such securities for the
three months ending March 31, 2005 and December 31, 2004 was ($227,816) and
($277,088), respectively, and has been recorded in accumulated other
comprehensive income, which is reported as part of shareholder's equity in the
Condensed Consolidated Balance Sheets.
3) CONCENTRATION OF CREDIT RISK
The Company is exposed to concentration of credit risk related to accounts
receivable that are generated from its distributors and customers. To manage
credit risk, the Company performs regular credit evaluations of its customers'
financial condition and provides allowances for potential credit losses, when
applicable. Concentrations of credit risk in the Company's total revenues for
the three-months ended March 31, 2005 and 2004, and accounts receivable as of
March 31, 2005 and December 31, 2004 are as follows:
% OF REVENUE
---------------------------- -------------------------------
THREE-MONTHS ENDED % OF ACCOUNTS RECEIVABLE
---------------------------- -------------------------------
MARCH 31, MARCH 31, MARCH 31, DECEMBER 31,
2005 2004 2005 2004
------------ ------------ ------------ ---------------
Third-party distributor A 15% 39% 8% 27%
Third-party distributor B - 29% - -
Third-party distributor C 13% - 47% 34%
Direct customer distribution 72% 32% 45% 39%
------------ ------------ ------------ ---------------
Total 100% 100% 100% 100%
============ ============ ============ ===============
6
DUSA PHARMACEUTICALS, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
4) INVENTORY
Inventory consisted of the following:
MARCH 31, 2005 DECEMBER 31,
(UNAUDITED) 2004
---------------- ----------------
Finished goods $1,409,511 $1,226,071
Work in process 333,621 85,910
Raw materials 247,119 105,179
---------------- ----------------
$1,990,251 $1,417,160
================ ================
5) OTHER ACCRUED EXPENSES
Other accrued expenses consisted of the following:
MARCH 31,
2005 DECEMBER 31,
(UNAUDITED) 2004
--------------- ---------------
Research and development costs $511,737 $ 778,926
Marketing and sales costs 174,560 153,167
Product related costs 612,423 261,444
Legal and other professional fees 400,682 374,142
Employee benefits 239,978 229,304
Other expenses 83,037 104,858
--------------- ---------------
$2,022,417 $1,901,841
=============== ===============
6) ACCOUNTING FOR STOCK BASED COMPENSATION
SFAS No. 123, as amended by SFAS No. 148, addresses the financial
accounting and reporting standards for stock or other equity-based compensation
arrangements. The Company has elected to continue to use the intrinsic
value-based method to account for employee stock option awards under the
provisions of Accounting Principles Board Opinion No. 25, "Accounting for Stock
Issued to Employees," and to provide disclosures based on the fair value method
in the Notes to the Consolidated Financial Statements as permitted by SFAS No.
123, as amended by SFAS No. 148. Under the intrinsic value method, compensation
expense, if any, is recognized for the difference between the strike price of
the option and the fair value of the underlying common stock as of a measurement
date. The measurement date is the time when both the number of shares and the
strike price is known. Stock or other equity-based compensation for
non-employees must be accounted for under the fair value-based method as
required by SFAS No. 123, as amended by SFAS No. 148, and EITF No. 96-18, and
other related interpretations. Under this method, the equity-based instrument is
valued at either the fair
7
DUSA PHARMACEUTICALS, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
value of the consideration received or the equity instrument issued on the
measurement date, which is generally the grant date. The resulting compensation
cost is recognized and charged to operations over the service period, which is
generally the vesting period.
In March 2005, the vesting period for 18,875 options to purchase shares of
common stock was extended beyond the original terms and the vesting of 1,250
options was accelerated upon an employee's termination. As a result of this
stock option modification, the Company recorded compensation expense of
approximately $19,000 during the three months ending March 31, 2005. The
compensation expense was calculated using the intrinsic value method, which
compares the common stock option exercise price to the fair market value of the
underlying common stock on the date of modification. The stock compensation
expense was recorded as part of general and administrative costs in the
Condensed Consolidated Statement of Operations.
As described above, the Company uses the intrinsic value method to measure
compensation expense associated with grants of stock options to employees. Had
the Company used the fair value method to measure compensation, the Company's
pro forma net loss, and pro forma net loss per share for the three months ending
March 31, 2005 and 2004 would have been as follows:
MARCH 31, MARCH 31,
2005 2004
(UNAUDITED) (UNAUDITED)
--------------- ---------------
Net loss: as reported $(4,331,615) $(4,401,654)
Deduct: effect on net loss if fair value method had been
used (322,173) (717,145)
--------------- ---------------
Net loss: proforma $(4,653,788) $(5,118,799)
=============== ===============
Basic and diluted net loss per common share: as reported $(0.26) $(0.30)
--------------- ---------------
Basic and diluted net loss per common share: proforma $(0.28) $(0.35)
=============== ===============
In December 2004, the Financial Accounting Standards Board ("FASB") issued
SFAS Statement No. 123(R), "Share-Based Payment," a revision of SFAS Statement
No. 123, which will impact the accounting for employee stock options and other
equity-based compensation. The standard requires companies to measure and
recognize compensation expense for all stock-based payments at fair value. The
adoption of SFAS No. 123(R) will not affect the Company's cash flow or financial
position, but it will affect the Company's net income (loss) and earnings (loss)
per share. In accordance with the revised statement and the Securities and
Exchange Commission's recent ruling that defers the required effective date of
adoption, the Company will recognize the expense attributable to stock options
that are granted or vest in periods subsequent to December 31, 2005. As noted
above, had the Company expensed its employee stock options under SFAS No. 123
for the three months ended March 31, 2005, net loss and net loss per share
8
DUSA PHARMACEUTICALS, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
would have increased by approximately $322,000, or $0.02 per share,
respectively. As stock option grants are determined throughout each year, the
increase or decrease in stock compensation expense as a result of adoption of
SFAS No. 123(R) cannot be predicted with certainty.
7) BASIC AND DILUTED NET LOSS PER SHARE
Basic net loss per common share is based on the weighted-average number of
shares outstanding during each period. For the three months ended March 31,
2005, and 2004, stock options, warrants and rights totaling approximately
3,386,000 and 3,396,000 shares, respectively, have been excluded from the
computation of diluted net loss per share as the effect would be antidilutive.
8) COMPREHENSIVE LOSS
For the three months ended March 31, 2005 and 2004, comprehensive loss
consisted of the following:
MARCH 31, MARCH 31,
2005 2004
(UNAUDITED) (UNAUDITED)
--------------- ----------------
NET LOSS $(4,331,615) $(4,401,654)
Change in net unrealized gains and losses on
marketable securities available for sale (227,816) (147,659)
--------------- ----------------
COMPREHENSIVE LOSS $(4,559,431) $(4,549,313)
=============== ================
Accumulated other comprehensive income consists of net unrealized gains and
losses on marketable securities available for sale, which is reported as part of
shareholders' equity in the Condensed Consolidated Balance Sheets.
9) COMMITMENTS AND CONTINGENCIES
Legal Matters - On April 12, 2002, the Company received notice that one of
the patents licensed to the Company by PARTEQ Research & Development
Innovations, the technology transfer arm of Queen's University at Kingston,
Ontario was being challenged by PhotoCure ASA. PhotoCure ASA filed a lawsuit in
Australia alleging that Australian Patent No. 624985, which is one of the
patents relating to the Company's 5-aminolevulinic acid technology, is
9
DUSA PHARMACEUTICALS, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
invalid. As a consequence of this action, Queen's University assigned the
Australian patent to the Company so that DUSA could participate directly in this
litigation. The Company filed a response setting forth its defenses, and a
related countersuit alleging that certain activities of PhotoCure and its
marketing partner, Galderma S.A., infringed the patent. The final hearing in the
Federal Court of Australia was held in April 2004. On April 6, 2005, the Federal
Court of Australia ruled that the Australian patent is valid and remains in full
force and effect. However, the Court also ruled that PhotoCure's product,
Metvix, does not infringe the claims in the Australian patent. None of the
parties filed an appeal and the time period for doing so has expired. Since
these claims are unique to the Australian patent, the Company does not expect
this ruling to be determinative of the validity of any other patents licensed by
DUSA from Queen's University or of whether Metvix infringes claims in such other
patents, including the United States patent. As DUSA does not have an active
drug application in Australia, DUSA believes that this ruling will have no
operational impact on the Company.
In December 2004, we filed a lawsuit against New England Compounding
Pharmacy, Inc. of Framingham, Massachusetts alleging violations of U.S. patent
law in the United States District Court in Boston, Massachusetts. On March 17,
2005, New England Compounding Pharmacy filed an answer against us, including a
defense that our patents are invalid and counterclaims, and we filed our
response on April 5, 2005. In January 2005, we filed a lawsuit against The
Cosmetic Pharmacy of Tucson, Arizona alleging violations of the Lanham Act for
false advertising and trademark infringement, and of U.S. patent law in the U.S.
District Court for the District of Arizona. A default was entered on May 2, 2005
since no answer was filed. We are seeking injunctive relief, monetary damages
and costs in both lawsuits. These cases are in their early stages and the
Company is unable to predict the outcomes at this time.
The Company has not accrued any amounts for settlement as of March 31,
2005.
10
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
OVERVIEW
DUSA is a pharmaceutical company engaged primarily in the research,
development, and marketing of a drug named 5-aminolevulinic acid, or ALA, which
is used in combination with appropriate light devices in order to detect or
treat a variety of medical conditions. The trademark for our brand of ALA is
Levulan(R). When Levulan(R) is used and followed with exposure to light to
produce a therapeutic effect, the technology is called photodynamic therapy, or
PDT. When Levulan(R) is used and followed with exposure to light to detect
medical conditions, the technology is called photodetection, or PD. Our products
are Levulan(R) 20% topical solution using our Kerastick(R) brand applicator, and
our BLU-U(R) brand light unit. Our products are used together to provide PDT for
the treatment of non-hyperkeratotic actinic keratoses, or AKs, of the face or
scalp. In addition, the BLU-U(R) is used without Levulan(R) for the treatment of
moderate inflammatory acne vulgaris and general dermatological conditions. Both
products have received approval or market clearance as required from the United
States Food and Drug Administration ("FDA") and regulatory approval from Health
Canada. We are currently conducting clinical trials to test whether our products
can be used to treat both photodamaged skin and acne with Levulan(R) PDT.
Since the October 2003 launch of our sales force, sales and revenues of our
products have increased substantially. Kerastick(R) unit sales to end-users were
28,704 for the three months ended March 31, 2005, consisting of 24,900 sold in
the United States, and 3,804 sold by Coherent-AMT, our Canadian marketing and
distribution partner. This represents an increase of 107% in the United States
and an overall increase of 138% when compared to the 12,054 Kerastick(R) units
sold solely in the United States during the three months ended March 31, 2004,
prior to the Canadian launch.
The net number of BLU-U(R) units placed in doctors' offices during the
three months ended March 31, 2005 was 131, including 31 placed in Canada. As of
March 31, 2005 there were 1,045 units in doctor's offices, consisting of 913 in
the United States and 132 in Canada. There were 914 BLU-U(R) units in doctors'
offices at December 31, 2004, consisting of 813 in the United States and 101 in
Canada.
We have continued our efforts to penetrate the market by expanding our
sales coverage in key geographic locations. As of March 31, 2005, our direct
sales force consisted of 31 employees, including representatives and management,
compared to 22 at the end of 2004. See section entitled "Results of Operations -
Marketing and Sales Costs". To date, we are
11
encouraged with the quarterly increases in sales and the positive trends we are
seeing in such key metrics as number of reordering customers and new customers,
although the costs related to the expansion of our sales force and related
marketing activities are significant as compared to the revenue generated from
the increased sales volumes. During this quarter, approximately 1,000 customers
ordered Kerastick(R) units, of which approximately two-thirds were existing
customers and one-third were new customers, as compared to approximately 1,600
customers who ordered product during all of 2004. However, due to various
factors, including, but not limited to, a price increase which had been
announced prior to its November, 2004 effective date, and certain volume
discount programs which had been in place for much of 2004, we believe that
physicians ordered more Kerastick(R) units than their usage may have
necessitated at that time. As a result, approximately 60% of our top 100
customers did not order Kerastick(R) units in this quarter and, in some cases,
may still be working down their supplies through the second quarter.
Historically, we have primarily devoted our resources to fund research and
development in order to advance the Levulan(R) PDT/PD technology platform and,
as a result, we have experienced significant operating losses. As of March 31,
2005, we had an accumulated deficit of approximately $78,870,000. We expect to
continue to incur operating losses until sales of our products increase
substantially. Achieving our goal of becoming a profitable operating company is
dependent upon greater acceptance of our therapy by the medical and consumer
constituencies, and our ability to develop and/or acquire new profitable
products.
We believe that issues related to reimbursement have negatively impacted
the economic competitiveness of our therapy with other AK therapies and have
hindered its adoption in the past. Effective January 1, 2005, the CMS average
national reimbursement for the use of Levulan(R) PDT for AKs was increased,
reflecting the cost of additional medical supplies that were not included in the
original application. However, a change in 2005 to the way the drug is
reimbursed, which is now based on the average selling price (ASP) rather than
the average wholesale price (AWP), caused a decrease in the amount reimbursed
for the Kerastick(R). Going forward, reimbursement for the Kerastick(R) will
vary from quarter to quarter, calculated as 106% of the ASP to the end-user
during a prior quarter, including all discounts. As DUSA has already started to
decrease its Kerastick(R) volume discount programs, reimbursement is expected to
increase in future quarters. Overall, we believe that 2005 reimbursement changes
related to treatment of AK are positive for doctors using our therapy. However,
we are aware that some physicians still believe that even the new reimbursement
levels do not fully reflect the required efforts to routinely execute our
therapy in their practices. DUSA believes that the reimbursement codes which
apply to Levulan(R) PDT will be reexamined within a five-year review cycle. It
is difficult to predict the effect of the 2005 changes at this time. DUSA
continues to support ongoing efforts that might lead to further increases in
reimbursement and intends to support efforts to seek reimbursement for our
FDA-cleared use of the BLU-U(R) alone in the treatment of mild to moderate
inflammatory acne.
In addition, we continue to work to educate private insurance carriers so
that they will approve our therapy for coverage. Several of the major private
insurers have approved coverage for our AK therapy. We believe that due to these
efforts, along with our education and marketing programs, a more widespread
adoption of our therapy should occur over time.
We have been encouraged by the positive response from many physicians and
patients who have used our therapy, but we recognize that we have to continue to
demonstrate the clinical value of our unique therapy, and the related product
benefits as compared to other well-established conventional therapies, in order
for the medical community to accept our products on
12
a large scale. While our financial position is strong, we cannot predict when
product sales may offset the costs associated with these efforts. We are aware
that physicians have been using Levulan(R) with the BLU-U(R), and with light
devices manufactured by other companies, for uses other than our FDA-approved
use. While we are not permitted to market our products for so-called 'off-label'
uses, we estimate, based on limited in-house survey data, that these activities
are positively affecting the sales of our products and may represent a greater
percentage of our total sales than the usage of our products for the treatment
of AKs.
We are also aware that some compounding pharmacies may be exceeding the
legal limits for their activities, including manufacturing and/or selling
quantities of ALA in circumstances which may be inducing purchasers to infringe
our intellectual property. These activities may be negatively impacting our
sales growth. Therefore in December, 2004 and in January, 2005, we filed
lawsuits against two compounding pharmacies. See "Part II, Item 1, Litigation."
During the quarter, we increased the size of our sales force to 31 from 22
at the end of 2004. As of March 31, 2005, our staff included 80 full-time
employees and 4 part-time employees as compared to 65 full-time employees and 4
part-time employees at the end of 2004. These include marketing and sales,
production, maintenance, customer support, and financial operations personnel,
as well as those who support research and development programs for dermatology
and internal indications. We may add and/or replace employees throughout 2005 as
business circumstances deem necessary.
On January 4, 2005, we announced the appointment by DUSA's Board of
Directors of Mr. Robert F. Doman as our President and Chief Operating Officer
effective January 3, 2005. As a result of Mr. Doman joining DUSA, Dr. D.
Geoffrey Shulman resigned his position as President of the Company and Mr. Jay
Haft resigned as Chairman of the Board of Directors also effective January 3,
2005. Dr. Shulman remains as DUSA's Chief Executive Officer and has been
re-appointed to the position of Chairman of the Board of Directors. Mr. Haft
retains his position as Lead Director and has been appointed to the position of
Vice Chairman of the Board of Directors. During the quarter we also announced
the hiring of Mr. Gary Talarico as Vice President, Sales, and the promotion of
Mr. Richard Christopher to Vice President, Finance and Chief Financial Officer.
We believe that DUSA is now much better positioned to take advantage of the
market opportunities for Levulan(R) PDT in dermatology and other fields. With
our strengthened management team, increased sales force, and a variety of
educational and marketing initiatives, we anticipate significant year-over-year
increases in sales going forward, although variability in quarterly growth rates
at this early stage of the adoption curve is still to be expected. Now that we
have a specialty dermatology sales force, we are also actively working on
in-licensing and/or developing additional dermatology products; while continuing
to work on out-licensing Levulan(R) PDT for dermatology in territories outside
of North America.
13
CRITICAL ACCOUNTING POLICIES
Our accounting policies are disclosed in Note 2 to the Notes to the
Consolidated Financial Statements in our Annual Report on Form 10-K for the year
ended December 31, 2004. Since all of these accounting policies do not require
management to make difficult, subjective or complex judgments or estimates, they
are not all considered critical accounting policies. We have discussed these
policies and the underlying estimates used in applying these accounting policies
with our audit committee. We consider the following policies and estimates to be
critical to our financial statements.
REVENUE RECOGNITION - Revenues on product sales are recognized when
persuasive evidence of an arrangement exists, the price is fixed and final,
delivery has occurred, and collection is probable. Product sales made through
distributors who have a general right of return of product have been recorded as
deferred revenue until the product is sold by our distributors to the end user.
Although we make every effort to assure the reasonableness of our estimates,
significant unanticipated changes in our estimates due to business, economic, or
industry events could have a material impact on our results of operations.
INVENTORY - Inventories are stated at the lower of cost or market. Cost is
determined using the first-in, first-out method. Inventories are continually
reviewed for slow moving, obsolete and excess items. Inventory items identified
as slow-moving are evaluated to determine if an adjustment is required.
Additionally, our industry is characterized by regular technological
developments that could result in obsolete inventory. Although we make every
effort to assure the reasonableness of our estimates, any significant
unanticipated changes in demand, technological development, or significant
changes to our business model could have a significant impact on the value of
our inventory and our results of operations. We use sales projections to
estimate the appropriate level of inventory reserves necessary at each balance
sheet date. Management believes that the recorded value of inventory as of March
31, 2005 is reasonable in light of our current sales forecasts.
VALUATION OF LONG-LIVED AND INTANGIBLE ASSETS - We review long-lived assets
for impairment whenever events or changes in business circumstances indicate
that the carrying amount of assets may not be fully recoverable or that the
useful lives of these assets are no longer appropriate. Factors that we consider
important which could trigger an impairment review include significant changes
relative to: (i) projected future operating results; (ii) the use of the assets
or the strategy for the overall business; (iii) business collaborations; and
(iv) industry, business, or economic trends and developments. Each impairment
test is based on a comparison of the undiscounted cash flow to the recorded
value of the asset. If it is determined that the carrying value of long-lived or
intangible assets may not be recoverable based upon the existence of one or more
of the above indicators of impairment, the asset is written down to its
estimated
14
fair value on a discounted cash flow basis. At March 31, 2005, our total
property, plant and equipment had a carrying value of $3,413,000, including
$1,925,000 associated with our manufacturing facility. As of March 31, 2005, we
had intangible assets totaling $264,000 recorded in deferred charges and other
assets relating to the unamortized balance of payments incurred in 2004 to
National Biological Corporation to amend our agreement to develop and
manufacture light sources, and to Draxis Health, Inc., our former parent, to
reacquire our product rights in Canada.
STOCK-BASED COMPENSATION - We have elected to continue to use the intrinsic
value-based method to account for employee stock option awards under the
provisions of Accounting Principles Board Opinion No. 25, and to provide
disclosures based on the fair value method in the Notes to the Consolidated
Financial Statements as permitted by Statement of Financial Accounting Standards
("SFAS") No. 123, "Accounting for Stock Compensation," as amended by SFAS No.
148, "Accounting for Stock-Based Compensation, Transition and Disclosure". Stock
or other equity-based compensation for non-employees is accounted for under the
fair value-based method as required by SFAS No. 123 and Emerging Issues Task
Force ("EITF") No. 96-18, "Accounting for Equity Instruments That Are Issued to
Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or
Services" and other related interpretations. Under this method, the equity-based
instrument is valued at either the fair value of the consideration received or
the equity instrument issued on the date of grant. The resulting compensation
cost is recognized and charged to operations over the service period, which, in
the case of stock options, is generally the vesting period.
In December 2004, the Financial Accounting Standards Board issued SFAS No.
123(R), "Share-Based Payment," a revision of SFAS No. 123, which will impact the
accounting for employee stock options and other equity-based compensation. The
standard requires companies to measure and recognize compensation expense for
all stock-based payments at fair value. The adoption of SFAS No. 123(R) will not
affect our cash flow or financial position, but it will affect our net income
(loss) and earnings (loss) per share. In accordance with the revised statement
and the Securities and Exchange Commission's recent ruling that defers the
required effective date of adoption, we will recognize the expense attributable
to stock options that are granted or vest in periods subsequent to December 31,
2005. As described in Note 6 to the Notes to the Condensed Consolidated
Financial Statements, had the Company expensed its employee stock options under
SFAS No. 123 for the three months ended March 31, 2005, net loss and net loss
per share would have increased by approximately $322,000, or $0.02 per share,
respectively. As stock option grants are determined throughout each year, the
increase or decrease in stock compensation expense as a result of the adoption
of SFAS No. 123(R) cannot be predicted with certainty.
15
RESULTS OF OPERATIONS - THREE MONTHS ENDING MARCH 31, 2005 VERSUS MARCH 31, 2004
REVENUES - Total revenues for the three months ended March 31, 2005 were
$3,369,000 as compared to $1,256,000 in 2004, and were comprised of the
following:
THREE MONTHS ENDED MARCH 31,
(UNAUDITED)
-------------------------------------------
2005 2004 INCREASE/
(DECREASE)
------------ ------------ -----------
KERASTICK(R) PRODUCT REVENUES
United States $2,249,000 $896,000 $1,353,000
Canada 261,000 - 261,000
------------ ------------ -----------
Total 2,510,000 896,000 1,614,000
BLU-U(R) PRODUCT REVENUES
United States 686,000 360,000 326,000
Canada 173,000 - 173,000
------------ ------------ -----------
Total 859,000 360,000 499,000
------------ ------------ -----------
Total product revenues $3,369,000 $1,256,000 $2,113,000
============ ============ ===========
The increase in 2005 Kerastick(R) revenues was driven mainly by increased
sales volumes. Kerastick(R) sales to end-users for the three months ended March
31, 2005 totaled 28,704 units versus 12,054 units in the comparable 2004 period.
The 2005 total consists of 24,900 sold in the United States and 3,804 sold by
Coherent-AMT, our Canadian marketing and distribution partner. All first quarter
2004 units were all sold in the United States, as the Canadian launch had not
yet occurred. The increase in revenues is also attributable to our decision to
increase our average unit selling price as of November 2004, increased levels of
our direct distribution to customers, and a reduction in our overall sales
volume discount programs. In fact, our average net selling price for the
Kerastick(R) increased to $87.44 in the first quarter of 2005 from $74.27 in the
first quarter of 2004.
The increase in 2005 BLU-U(R) revenue was driven by both increased sales
volumes and an increase in our average selling price. There were 143 units sold
for the three months ended March 31, 2005 versus 109 units sold in the
comparable 2004 period. The 2005 total consists of 112 units sold in the United
States and 31 sold in Canada by Coherent-AMT. The 109 units from 2004 were all
sold in the United States. During the quarter, we received a new supply of
BLU-U(R) units, and are now in a positive inventory position.
16
' The increase of both Kerastick(R) and BLU-U(R) revenues is a result of the
efforts of our sales force and related marketing and sales activities including
our participation at the American Academy of Dermatology ("AAD") annual meeting
in February 2005, which is the largest and most important dermatology conference
each year in the United States. With respect to United States Kerastick(R)
sales, we increased the price last November and will continue to evaluate the
market during the year. We have increased our direct selling and distribution
efforts, while still maintaining the services of one external distributor, and
we have reduced our overall sales volume discount programs, all of which we
believe have had a positive impact on sales this quarter. We also believe,
however, that due to the various factors mentioned above, physicians may have
ordered more Kerastick(R) units than their usage necessitated at that time. As a
result, approximately 60% of our top 100 customers from 2004 did not order
Kerastick(R) units in this quarter and, in some cases, may be working down their
supplies through the second quarter. We expect to continue to increase our
internal distribution capabilities in order to increase our gross revenue and
net profit per unit. However, our costs will also increase to support this
function. Although the level of Kerastick(R) sales to end-users for 2005 is
higher than those in the prior year, Kerastick(R) sales must continue to
increase significantly in order for us to become profitable.
COST OF PRODUCT SALES AND ROYALTIES - Cost of product sales and royalties
for the three months ended March 31, 2005 were $2,004,000 as compared to
$826,000 in 2004. A summary of the components of cost of product sales and
royalties is provided below:
THREE MONTHS ENDED MARCH 31,
(UNAUDITED)
-------------------------------------------
KERASTICK(R) COST OF PRODUCT SALES AND ROYALTIES 2005 2004 INCREASE/
(DECREASE)
------------ ------------ -----------
Direct Kerastick(R) Product costs $580,000 $233,000 $347,000
Other Kerastick(R) Product costs including internal costs
assigned to support products 272,000 162,000 110,000
Royalty and supply fees (1) 128,000 36,000 92,000
------------ ------------ -----------
Total Kerastick(R) cost of product sales and
royalties $980,000 $431,000 $549,000
------------ ------------ -----------
-------------------------------------------
BLU-U(R) COST OF PRODUCT SALES 2005 2004 INCREASE/
(DECREASE)
------------ ------------ -----------
Direct BLU-U(R) Product costs (2) $476,000 $- $476,000
Other BLU-U(R) Product costs including internal costs
assigned to support products; as well as costs incurred
to ship, install and service the BLU-U(R) in physicians
offices 548,000 395,000 153,000
------------ ------------ -----------
Total BLU-U(R) cost of product sales $1,024,000 $395,000 $629,000
------------ ------------ -----------
TOTAL COST OF PRODUCT SALES AND ROYALTIES $2,004,000 $826,000 $1,178,000
============ ============ ===========
1) Royalty and supply fees reflect amounts paid to our licensor, PARTEQ
Research and Development Innovations, the licensing arm of Queen's
University, Kingston, Ontario and
17
amortization of an upfront fee and ongoing royalties paid to Draxis,
DUSA's former parent, on sales of the Levulan(R) Kerastick(R) in
Canada.
2) Although there were direct BLU-U(R) product sales in 2004, there were no
related direct BLU-U(R) product costs as these units had a zero book
value due to inventory impairment charges recorded during 2002.
GROSS MARGIN - Total product margins for the three months ended March 31,
2005 were $1,365,000 as compared to $430,000 for the comparable 2004 period, as
shown below:
-----------------------------------------------------
THREE MONTHS ENDED MARCH 31,
(UNAUDITED)
-----------------------------------------------------
2005 2004 INCREASE/
(DECREASE)
-----------------------------------------------------
KERASTICK(R) $1,530,000 61% $465,000 52% $1,065,000
BLU-U(R) (165,000) (19%) (35,000) (10%) (130,000)
------------ ---------- ------------
Total Gross Margin $1,365,000 41% $430,000 34% $935,000
============ ========== ============
Kerastick(R) gross margins for the three months ended March 31, 2005 were
61% versus 52% for the comparable 2004 period. Similar to the increase in
revenues, the increase in margin is attributable to our decision to increase our
average unit selling price as of November 2004, increased levels of direct
distribution to customers; as well as a reduction in our overall sales volume
discount programs. Our long-term goal is to achieve much higher gross margins on
Kerastick(R) sales which will be significantly dependent on increased volume.
BLU-U(R) gross margins for the three months ended March 31, 2005 were
negative 19% versus negative 10% for the comparable 2004 period. The erosion on
margin is directly attributable to the fact that in the first quarter of 2005 we
sold newly purchased units with an associated production cost, whereas during
the comparable 2004 period, we sold units which had a zero net book value due to
inventory impairment charges recorded during 2002 following termination of an
agreement with a marketing partner. The erosion is somewhat offset by an
increase in the overall selling price per unit. Also, this quarter we sold most
of the units at a discounted price at the major medical conferences we attended,
which also affected our margins. Our short-term strategy is to approach
breakeven on device sales in an effort to drive Kerastick(R) sales volumes.
However, our longer term goal is to move towards a reasonable profit margin on
all device sales.
RESEARCH AND DEVELOPMENT COSTS - Research and development costs for the
three months ended March 31, 2005 were $1,596,000 as compared to $1,688,000 in
2004. We have commenced Part B (the efficacy phase) of our Phase II photodamaged
skin study, and completed
18
enrollment in the first of three cohorts of the Phase II multi-center acne
study, treating 24 patients with a total of 81 PDT sessions. It is anticipated
that we will have primary efficacy and safety data for both of the Phase II
studies around year end 2005. As our Phase II clinical trials proceed, and
especially at such time as we may commence Phase III trials in these
indications, research and development expenses are expected to increase
significantly. We also continue to examine the costs and regulatory requirements
associated with seeking foreign marketing approvals for our products, which
could cause research and development expenses to increase.
DUSA has also been following patients who completed Phase I/II studies in
the treatment of high-grade and low-grade dysplasia associated with Barrett's
esophagus. On September 27, 2004, DUSA signed a clinical trial agreement with
the National Cancer Institute, Division of Cancer Prevention, or NCI DCP, for
the clinical development of Levulan(R) PDT for the treatment of high-grade
dysplasia within Barrett's Esophagus. In addition, to further our objectives
concerning treatment of internal indications using Levulan(R) photodynamic
therapy ("PDT"), on November 4, 2004 we signed an additional clinical trial
agreement with the NCI DCP for the treatment of oral cavity dysplasia. DUSA and
the NCI DCP are working together to prepare overall clinical development plans
for Levulan(R) PDT in these indications, starting with Phase II trials, and
continuing through Phase III studies, if appropriate. The immediate plan is for
the NCI DCP to solicit clinical protocols from its extramural expert clinical
investigator consortium, after which time DUSA and the NCI DCP will finalize the
clinical trial designs. The NCI DCP will use its resources to file its own
Investigational New Drug applications with the FDA. DUSA will provide
Levulan(R), device(s) and the necessary training for the investigators involved
in the studies, and is in the process of estimating DUSA's incremental costs of
this program. DUSA will maintain full ownership of its existing intellectual
property, has options on new intellectual property and, subject to successful
Phase II and III clinical trial results, intends to seek FDA approvals in due
course. In preparation for new Phase II clinical trials for the treatment of
high-grade dysplasia associated Barrett's esophagus, we have initiated a small
single-center pilot Phase II clinical trial using DUSA's new proprietary
endoscopic light delivery device.
During the quarter, we also received the Notice of Final Determination for
the Hatch-Waxman Patent Term Extension for Actinic Keratoses, which will extend
our patent claims that cover AK from July 2009 to October 2013.
MARKETING AND SALES COSTS - Marketing and sales costs for the three months
ended March 31, 2005 were $2,785,000 as compared to $1,367,000 for 2004. These
costs consist primarily of expenses such as salaries and benefits for the
marketing and sales staff, commissions, and related support expenses such as
travel, and telephone, totaling $1,837,000 for the three month period ended
March 31, 2005, compared to $1,016,000 in 2004. These increases were mainly
attributable to the expansion of our sales force from 8 employees as of March
31, 2004 to 31 employees as of March 31, 2005, including sales management. The
remaining
19
expenses consist of tradeshows, miscellaneous marketing and outside consultants
totaling $948,000 for the three month period ended March 31, 2005, compared to
$351,000 in 2004. We expect that our overhead expenses will remain elevated
reflecting the expansion of our sales capacity; however, these expenses should
be somewhat offset by lower tradeshow spending for the remainder of the year, as
the major conferences took place during the first quarter of 2005.
GENERAL AND ADMINISTRATIVE COSTS - General and administrative costs for the
three months ended March 31, 2005 decreased to $1,682,000 as compared to
$2,175,000 for 2004. This decrease is mainly attributable to lower legal
expenses of $419,000 incurred in 2005 as compared to $1,199,000 in 2004, due to
the absence of patent litigation costs in Australia as the final hearing in the
PhotoCure litigation described below was held in April 2004. The savings related
to the Australian litigation is partially offset by the litigation costs against
two compounding pharmacies also described below and higher levels of general
corporate expenses to support our expanding business, including an increase in
personnel related costs.
On April 12, 2002, we received notice that one of the patents licensed to
DUSA by PARTEQ Research & Development Innovations, the technology transfer arm
of Queen's University at Kingston, Ontario was being challenged by PhotoCure
ASA. PhotoCure ASA filed a lawsuit in Australia alleging that Australian Patent
No. 624985, which is one of the patents relating to our 5-aminolevulinic acid
technology, is invalid. As a consequence of this action, Queen's University
assigned the Australian patent to us so that we could participate directly in
this litigation. We filed a response setting forth our defenses, and a related
countersuit alleging that certain activities of PhotoCure and its marketing
partner, Galderma S.A., infringe the patent. The final hearing in the Federal
Court of Australia was held in April 2004. On April 6, 2005, the Federal Court
of Australia ruled that our Australian patent is valid and so it remains in full
force and effect. However, the Court also ruled that PhotoCure's product,
Metvix, does not infringe the claims in the Australian patent. None of the
parties filed an appeal and the time period for doing so has now expired. Since
these claims are unique to the Australian patent, we do not expect this ruling
to be determinative of the validity of any other patents licensed by us from
Queen's University or of whether Metvix infringes claims in such other patents,
including the United States patent. As DUSA does not have an active drug
application in Australia, we believe that this ruling will have no operational
impact. We continue to negotiate with PhotoCure and Galderma under the terms of
a Mediation Agreement signed by the parties in August 2004 in order to try to
facilitate a settlement of our differences with respect to certain of our other
patents licensed from PARTEQ.
In December 2004, we filed a lawsuit against New England Compounding
Pharmacy, Inc. ofFramingham, Massachusetts alleging violations of United States
patent law in the U.S. District Court in Boston, Massachusetts. On March 17,
2005, New England Compounding Pharmacy filed an answer against us, including a
defense that our patents are invalid and
20
counterclaims, and we filed our response on April 5, 2005. In January 2005, we
filed a lawsuit against The Cosmetic Pharmacy of Tucson, Arizona alleging
violations of the Lanham Act for false advertising and trademark infringement,
and the U.S. patent law in the U.S. District Court for the District of Arizona.
A default was entered on May 2, 2005 since no answer was filed. We are seeking
injunctive relief, monetary damages and costs in both lawsuits. We have not
reserved any funds for settlement or damages at this time. These cases are in
their early stages and we are unable to predict the outcomes at this time. While
we also believe that certain actions of these pharmacies go beyond the
activities which are permitted under the Food, Drug and Cosmetic Act and have
advised the FDA and local health authorities of our concerns, we cannot be
certain that our lawsuits will be successful in curbing the practices of these
pharmacies or that regulatory authorities will intervene to stop their
activities which we believe are having a negative impact on our business.
OTHER INCOME, NET - Other income for the three months ended March 31, 2005
decreased to $367,000, as compared to $399,000 during the same period in 2004.
This decrease was attributable to a reduction in our average investable cash
balances during 2004 and early 2005, as we used cash to support our operating
activities. During the three months ended March 31, 2004, we incurred interest
expense of $11,000 on borrowings associated with the construction of our
Kerastick(R) manufacturing facility.
NET LOSSES - We incurred a net loss of $4,332,000, or $0.26 per share, for
the three months ended March 31, 2005, as compared to a net loss of $4,402,000
or $0.30 per share for the comparable period in 2004. Net losses are expected to
continue until end-user sales offset the cost of launching our sales force and
marketing initiatives, and the costs for other business support functions.
LIQUIDITY AND CAPITAL RESOURCES
DUSA is in a strong cash position to continue to fund increased Levulan(R)
PDT sales and marketing expenses and current research and development activities
for our Levulan(R) PDT/PD platform. At March 31, 2005, we had approximately
$43,818,000 of total cash resources comprised of $713,000 of cash and cash
equivalents, marketable securities available for sale totaling $42,964,000, and
restricted cash of $141,000. As of March 31, 2005, these securities had yields
ranging from 2.54% to 7.84% and maturity dates ranging from April 1, 2005 to
June 15, 2008.
As of March 31, 2005, working capital (total current assets minus total
current liabilities) was $44,516,000 as compared to $48,799,000 as of December
31, 2004. Total current assets and total current liabilities decreased by
$4,807,000 and $524,000, respectively, during the three
21
months ended March 31, 2005 due primarily to cash used in operating activities
of $5,059,000, offset in part by cash provided by investing activities of
$2,672,000.
We believe that we have sufficient capital resources to proceed with our
current programs for Levulan(R) PDT, and to fund operations and capital
expenditures for the foreseeable future. We have invested our funds in liquid
investments, so that we will have ready access to these cash reserves, as
needed, for the funding of development plans on a short-term and long-term
basis.
We anticipate that the level of marketing and sales expenses and related
support functions will continue to increase in 2005 as we seek to expand our
sales coverage as a result of the initial success of our sales initiatives. We
are actively seeking to expand or enhance our business by using resources to
acquire by license, purchase or other arrangements, businesses, new
technologies, or products. For 2005, we are focusing primarily on increasing the
sales of the Levulan(R) Kerastick(R) and the BLU-U(R), and advancing our Phase
II studies for use of Levulan(R) PDT in photodamaged skin and acne.
DUSA has no off-balance sheet financing arrangements other than its
operating leases.
CONTRACTUAL OBLIGATIONS AND OTHER COMMERCIAL COMMITMENTS
There have been no material changes to our contractual obligations and
other commercial commitments from those presented in our Annual Report on Form
10-K for the year ended December 31, 2004.
INFLATION
Although inflation rates have been comparatively low in recent years,
inflation is expected to apply upward pressure on our operating costs. We have
included an inflation factor in our cost estimates. However, the overall net
effect of inflation on our operations is expected to be minimal.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our exposure to market risk for changes in interest rates relates primarily
to our investment portfolio. We do not use derivative financial instruments in
our investment portfolio. Our investment policy specifies credit quality
standards for our investments and limits the amount of credit exposure to any
single issue, issuer or type of investment. Our investments
22
consist of United States government securities and high grade corporate bonds.
All investments are carried at market value, which approximates cost.
As of March 31, 2005, the weighted average rate of return on our
investments was 5.21%. If market interest rates were to increase immediately and
uniformly by 100 basis points from levels as of March 31, 2005, the fair market
value of the portfolio would decline by $319,000. Declines in interest rates
could, over time, reduce our interest income.
ITEM 4. CONTROLS AND PROCEDURES
We carried out an evaluation, under the direction of our Chief Executive
Officer and Chief Financial Officer, of the effectiveness of the design and
operation of our disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)). Based upon that evaluation, the Chief Executive
Officer and Chief Financial Officer concluded that our disclosure controls and
procedures were effective as of March 31, 2005.
There have been no changes in our internal control over financial reporting
that occurred during the quarter ended March 31, 2005 that have materially
affected, or are reasonably likely to materially affect, DUSA's internal control
over financial reporting.
FORWARD-LOOKING STATEMENTS
This report, including the Management's Discussion and Analysis, contains
various "forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 which represent our expectations or beliefs concerning
future events, including, but not limited to statements regarding management's
goal of becoming profitable, beliefs regarding adoption of our therapy, impact
of the activities of compounding pharmacies on sales growth, expectations for
continuing operating losses, intention to focus on increasing sales and to
insure adequate supply of inventory, expectations regarding internal
distribution capabilities, beliefs regarding physician Kerastick(R) orders,
estimates regarding the effects of so-called 'off-label' use of our products,
expectations for research and development costs and costs and regulatory
requirements associated with seeking foreign marketing approvals for our
products, plans for conducting development programs with respect to photodamaged
skin and acne, expectations of increasing staff and marketing and sales
expenses, effects of unanticipated changes in estimates and forecasts, belief
regarding inventory levels, factors which could trigger impairment review,
beliefs concerning the effect of improved reimbursement (or failure to achieve
it) and beliefs regarding Levulan(R) PDT reimbursement codes, beliefs regarding
our education and marketing programs, continued participation at medical
conferences and potential sales activities, intentions to evaluate and pursue
licensing and acquisition opportunities, beliefs regarding hiring levels and
levels of legal expenses, expectations concerning the operational impact and
general effect of the ruling by the Federal Court of Australia regarding the
Australian patent, requirements of cash resources, potential impact on
conversion of government securities, need for additional funds for development,
levels of interest income and net losses, sufficiency of our capital resources,
expectations regarding accounting pronouncements, inflation, market
23
risks and controls and procedures. These forward-looking statements are further
qualified by important factors that could cause actual results to differ
materially from those in the forward-looking statements. These factors include,
without limitation, changing market and regulatory conditions, actual clinical
results of our trials, the impact of competitive products and pricing, the
timely development, FDA approval, and market acceptance of our products, the
maintenance of our patent portfolio and ability to obtain competitive levels of
reimbursement by third-party payors, and other risks noted in our SEC filings
from time to time, including our Form 10-K for the period ending December 31,
2004, none of which can be assured.
24
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
In December 2004, we filed a lawsuit against New England Compounding
Pharmacy, Inc. of Framingham, Massachusetts alleging violations of United States
patent law in the Federal District Court in Boston, Massachusetts. On March 17,
2005, New England Compounding Pharmacy filed an answer against us, including a
defense that our patents are invalid and counterclaims, and we filed our
response on April 5, 2005. In January 2005, we filed a lawsuit against The
Cosmetic Pharmacy of Tucson, Arizona alleging violations of the Lanham Act for
false advertising and trademark infringement, and the U.S. patent law in the
U.S. District Court for the District of Arizona. On May 2, 2005, a default was
entered for failure to file an answer to this complaint. We are seeking
injunctive relief, monetary damages and costs in both lawsuits. These cases are
in their early stages and we are unable to predict the outcomes at this time.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
None.
ITEM 5. OTHER INFORMATION.
None.
ITEM 6. EXHIBITS
a) Exhibit 31(a) - Rule 13a-14(a)/15d-14(a) Certification of the Chief
Executive Officer.
b) Exhibit 31(b) - Rule 13a-14(a)/15d-14(a) Certification of the Chief
Financial Officer.
25
c) Exhibit 32(a) - Certification of the Chief Executive Officer
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002; and
d) Exhibit 32(b) - Certification of the Chief Financial Officer
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
e) Exhibit 99(a) - Press Release dated May 9, 2005
26
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DUSA Pharmaceuticals, Inc.
By: /s/ D. Geoffrey Shulman
--------------------------------
D. Geoffrey Shulman
Director, Chairman and Chief Executive
Officer (principal executive officer)
Date: May 9, 2005 By: /s/ Richard C. Christopher
----------- --------------------------------
Richard C. Christopher
Vice President, Finance and Chief Financial
Officer (principal financial officer)
EXHIBIT INDEX
31(a) Rule 13a-14(a)/15d-14(a) Certification of the Chief Executive Officer.
31(b) Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer.
32(a) Certification of the Chief Executive Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002; and
32(b) Certification of the Chief Financial Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
99(a) Press Release dated May 9, 2005